Nycomed is sold to Takeda for €9.6 billion


News widgets and RSS feeds on


Friday, 20 May 2011
Takeda Pharmaceutical Company Limited and Nycomed A/S (“Nycomed”) jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.

That amount is equivalent to Skr86 billion for the company, which is 41 percent owned by private equity firm Nordic Capital, according to Swedish business daily Dagens Industri.
The deal is one of the five largest private equity firm has made so far. The purchase price represents a good business even for Nycomed's leadership, which took 9 percent of the company.


The boards of directors of each company unanimously approved the transaction which is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed’s U.S. dermatology business.
By Team

Print this article

What do you think about this article? Would you like to leave a comment? It will be much appreciated. You can also rate this article.

  • Should be Empty:

Scandinavian Companies & Market Magazine
(C) 2010  Granscole Establishment Sweden AB. Registered in Sweden as a Media Company. Organisation Number: 556782-6572
F-Skatt (VAT) Number: SE556782657201